Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 0.41 |
| ▸ | MTOR | P42345 | 14/20 | 0.41 |
| ▸ | RPTOR | Q8N122 | 6/20 | 0.40 |
| ▸ | MLST8 | Q9BVC4 | 6/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 6/20 | 0.37 |
| ▸ | RICTOR | Q6R327 | 4/20 | 0.37 |
| ▸ | MAPKAP1 | Q9BPZ7 | 4/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14270945 | 1.00 | PIK3CA (0.41) | PIK3CAMTORRPTORMLST8PIK3R1 | |
| SCHEMBL14270959 | 1.00 | PIK3CA (0.41) | PIK3CAMTORRPTORMLST8PIK3R1 | |
| SCHEMBL14270958 | 0.81 | CXCR3 (0.42) | PIK3CAMTORATR | |
| SCHEMBL14297604 | 0.81 | CXCR3 (0.42) | PIK3CAMTORATR | |
| SCHEMBL14297600 | 0.75 | ACACB (0.42) | PIK3CAMTORATR | |
| SCHEMBL14297592 | 0.75 | ACACB (0.42) | PIK3CAMTORATR | |
| SCHEMBL14270935 | 0.75 | ACACB (0.42) | PIK3CAMTORATR | |
| SCHEMBL14270931 | 0.75 | ACACB (0.42) | PIK3CAMTORATR | |
| SCHEMBL3684029 | 0.74 | KMT2A (0.46) | — | |
| SCHEMBL3947541 | 0.74 | POLB (0.55) | PIK3CAMTORRPTORMLST8PIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045525-A1 | Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045525-A1 | Piperazinyl-Pyridine Analogues | PRLHR, GPR27, GPR68 | PIK3CA 904/4885MTOR 1783/4885RPTOR 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.